Septic thrombophlebitis and severe methotrexate toxicity in a patient on peritoneal dialysis
Methotrexate (MTX) is commonly prescribed for inflammatory dermatologic conditions; however, dosing errors and impaired renal clearance can result in life-threatening toxicity. Patients with end-stage renal disease (ESRD) are at heightened risk due to reduced MTX elimination. We describe a case of severe MTX toxicity presenting with mucosal bleeding, pancytopenia, and hemodynamic instability following inadvertent daily dosing in a patient on peritoneal dialysis. During her hospital course, she developed septic thrombophlebitis associated with a hemodialysis catheter. Complex multidisciplinary care included rescue leucovorin, emergent hemodialysis, colony-stimulating growth factor, and intravenous antibiotics. She survived to discharge with a plan for continued hemodialysis, intravenous antibiotics, and urethroscopy for evaluation of genital ulcerations.
Authors
- Sophie Wolfe Galson (ORCID: https://orcid.org/0000-0003-4709-6006)
- John Ramos (ORCID: https://orcid.org/0000-0002-3164-9537)
- Junaid Qureshi
- Joshua Ferguson
- Amelia Ballesteros-Edwards
- Nadine Kramer
Institutions
- Duke University (US)
- Duke Medical Center (US)
- Duke University Health System (US)
- Duke University Hospital (US)
Publication Details
- Journal
- Journal of Dermatology for Physician Assistants
- Published
- 2026-09-28
- DOI
- https://doi.org/10.1097/jdpa.0000000000000123
- Primary Topic
- Chemotherapy-related skin toxicity
- Type
- article
- Field-Weighted Citation Impact
- 0.00